| Paris | |
| 0 | |
| Inventiva is a clinical stage drug-discovery company delivering breakthrough therapies in the area of oncology, fibrosis and rare diseases. | |
| Non-alcoholic steato-hepatitis (NASH),a severe and chronic form of non-alcoholic fatty liver disease has become a leading contributor to the need for liver transplantation. NASH increases 5 to 10 fold the risk of liver related mortality and is expected to become the leading cause of liver transplantation by 2020. There are no pharmaceutical treatments currently approved in NASH and treatment options are limited to lifestyle change, weight loss and to physical therapy such as bariatric surgery. The high level of unmet need, growing patient population (today in the US alone it is estimated that more than 30 million people have NASH, of which more than 14 million are at a fibrotic stage of the disease)and the commercial potential of the NASH market makes it an attractive opportunity for new drug development. Currently in Phase IIb in Nash. Systemic sclerosis (SSc) is a complex, multiorgan, rare disease, affecting the immune system, the microvascular system and the connective tissue. This disease involves mostly skin but also lung, heart, gastrointestinal tract and kidneys. Organ progressive failures make SSc a severe and lethal disease with a high death toll.Currently in phase IIb in SSc. Mucopolysaccharidoses (MPS) are a group of rare genetic disorders characterized by deficiency of lysosomal enzymes responsible for the normal degradation of glycosaminoglycans (GAGs) or mucopolysaccharides. The enzyme deficiency leads to progressive accumulation of GAGs in the lysosomes and to the development of various somatic and neurologic symptoms such as a large head (macrocephaly), a buildup of fluid in the brain (hydrocephalus), distinctive-looking facial features that are described as "coarse" and a large tongue (macroglossia). Currently in Phase I/II in MPS VI. |
|
| CREN Frederic | |
| http://www.inventivapharma.com/ | |
| Private Equity |
Fiche créée le 10/04/2016 par 
Guillaume vue 17 fois.